Article Text
PostScript
Letter
Brentuximab vedotin treatment associated with acute and chronic inflammatory demyelinating polyradiculoneuropathies
Statistics from Altmetric.com
Footnotes
CC and DP contributed equally.
Contributors GF, AE-L, GB, CC and DP wrote the manuscript. CD-P, MS, JL, LT, CM-R, BR, PC, CT, WN, KV, TM, TL, AW, LM, KB, NG and DA revised the manuscript for intellectual content.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests JL has received research grants and personal fees from Takeda pharmaceutical company. GF, CD-P, MS, LT, CM-R, BR, GB, CT, WN, KV, TM, TL, AW, LM, KB, NG, DA, AE-L, CC and DP declare that they have no conflict of interest.
Patient consent for publication Obtained.
Provenance and peer review Not commissioned; externally peer reviewed.